Discover more from Courageous Discourse™ with Dr. Peter McCullough & John Leake
Theoretical Vaccine Effectiveness for Novavax Unacceptably Low
Real World Study Disappointing for Non-Genetic Vaccine
By Peter A. McCullough, MD, MPH
If it came to forced COVID-19 vaccination against human will, I have said Novavax would be the choice since it gives a limited 5 mcg dose of the potentially lethal Spike protein and has no genetic material. The growing number of fatal side effects with mRNA vaccines and recent news of contamination with SV-40 cDNA has resulted in record low rates of booster uptake, currently at 1.3% of unwary Americans.
Mateo-Urdiales reported on 20,903 individuals who took the two shot primary series of Novavax. Theoretical vaccine effectiveness was shockingly low:
“Adjusted estimated vaccine effectiveness against notified SARS-CoV infections in those with partial vaccination (15 days after the first dose to 14 days after the second dose) was 23%(95%CI, 13%-33%), increasing after full vaccination to 31% (95%CI, 22%-39%). Estimated vaccine effectiveness was higher against symptomatic COVID-19, with an estimate of 31% (95%CI, 16%-44%) in those partially vaccinated and of 50% (95%CI, 40%-58%) in those fully vaccinated.”
If a vaccine cannot safely provide at least 50% protection for a year, it is not viable in my clinical practice. Sadly Novavax failed at both of these outcomes. With low-risk Omicron, and likely substantial natural immunity by Fall of 2022, only 26 infections led to hospitalization during the study period; 1 occurred during the reference period, 7 during partial vaccination, and 18 after full vaccination. No deaths were reported.
In summary, Novavax is probably the safest of all the COVID-19 vaccines because it does not use genetic technology. Sadly, it is useless against Omicron and cannot be recommended for any health benefit.
Please subscribe to Courageous Discourse as a paying or founder member so we can continue to bring you the truth.
Courageous Discourse™ with Dr. Peter McCullough & John Leake is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.
Peter A. McCullough, MD, MPH
President, McCullough Foundation
Mateo-Urdiales A, Sacco C, Petrone D, et al. Estimated Effectiveness of a Primary Cycle of Protein Recombinant Vaccine NVX-CoV2373 Against COVID-19. JAMA Netw Open. 2023;6(10):e2336854. doi:10.1001/jamanetworkopen.2023.36854